Income StatementBalance SheetCash FlowSegments
HCA Healthcare logo

HCA Healthcare Cash Flow Statement

Operating, investing, and financing cash movements

HCA Healthcare generated $13.0B in operating cash flow over the trailing twelve months. After $5.1B in capital expenditures, free cash flow was $7.9B. Free cash flow increased 0.6% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$13.0BNet Cash From Investing (TTM)-$5.2BNet Cash From Financing (TTM)-$7.9BCapital Expenditures (TTM)$5.1BDepreciation And Amortization Cf (TTM)$3.6BNet Change In Cash (TTM)$2.0B
Latest FilingQ1 2026
Report Date2026-04-29
Market Cap$87.4B
P/E Ratio12.87
ROE-138.34%

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other non-cash income (expense)-$61.0M-$53.0M-$48.0M-$45.0M-$49.0M-$67.0M
Change in accounts payable$282.0M-$1.0B$324.0M$705.0M$637.0M-$990.0M
Change in accounts receivable$854.0M$327.0M-$647.0M-$25.0M$439.0M$463.0M
Deferred income taxes$89.0M$492.0M$388.0M$434.0M—$435.0M
Depreciation and amortization$856.0M$860.0M$863.0M$889.0M$911.0M$930.0M
Other Non-Cash Income (Expense)-$61.0M-$53.0M-$48.0M-$45.0M-$49.0M-$67.0M
Other Non-cash Income (Expense)-$61.0M-$53.0M-$48.0M-$45.0M-$49.0M-$67.0M
Other Non-cash Income (Expense)-$61.0M-$53.0M-$48.0M-$45.0M-$49.0M-$67.0M
Net cash from operating activities$2.6B$1.7B$4.2B$4.4B$2.4B$2.0B
Net income$1.7B$1.8B$1.9B$1.9B$2.2B$1.9B
Other non-cash income (expense)-$61.0M-$53.0M-$48.0M-$45.0M-$49.0M-$67.0M
Non-cash interest expense$9.0M$11.0M$14.0M$7.0M$12.0M$11.0M
Gain/(loss) on dispositions, net—$1.0M-$3.0M-$2.0M$41.0M-$1.0M
Increase Decrease In Inventories And Other Operating Assets-$150.0M$360.0M$67.0M—$29.0M-$80.0M
Other Noncash Income (Expense)-$61.0M-$53.0M-$48.0M-$45.0M-$49.0M-$67.0M
Other Non-cash Income and Expense-$61.0M-$53.0M-$48.0M-$45.0M-$49.0M-$67.0M
Other Non-Cash Adjustments-$61.0M-$53.0M-$48.0M-$45.0M-$49.0M-$67.0M
Other Non-Cash Income and Expense-$61.0M-$53.0M-$48.0M-$45.0M-$49.0M-$67.0M
Stock-based compensation$85.0M$98.0M$99.0M$104.0M$100.0M$86.0M

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Payments to acquire interest in subsidiaries and affiliates$42.0M$227.0M$99.0M$35.0M$36.0M$265.0M
Capital expenditures$1.3B$991.0M$1.2B$1.3B$1.5B$1.1B
Payment for (Proceeds from) Other Investing Activity$5.0M$3.0M-$5.0M$8.0M-$18.0M$4.0M
Net cash from investing activities-$1.3B-$1.0B-$1.3B-$1.4B-$1.3B-$1.3B
Net Payments for or Proceeds from Investments$30.0M-$28.0M-$13.0M$67.0M-$98.0M-$103.0M
Proceeds from sale of businesses$16.0M$161.0M$6.0M$10.0M$92.0M$3.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from lines of credit—$220.0M$1.5B$138.0M$296.0M$1.4B
Proceeds from issuance of debt—$5.2B——$3.2B$0.0
Repayments of debt$64.0M$3.9B$1.8B$174.0M$1.6B$58.0M
Dividends paid$165.0M$180.0M$171.0M$166.0M$162.0M$183.0M
Payments Of Debt Issuance Costs—$57.0M——$22.0M$0.0
Payments to Noncontrolling Interests$181.0M$220.0M$174.0M$237.0M$196.0M$191.0M
Other, net-$53.0M-$90.0M-$22.0M-$30.0M-$43.0M-$262.0M
Payment of Deferred Purchase Consideration-$53.0M-$90.0M-$22.0M-$30.0M-$43.0M-$262.0M
Noncontrolling interest transactions and other-$53.0M-$90.0M-$22.0M-$30.0M-$43.0M-$262.0M
Net cash from financing activities-$2.2B-$1.5B-$3.1B-$3.0B-$999.0M-$830.0M
Noncontrolling Interests Activity and Other-$53.0M-$90.0M-$22.0M-$30.0M-$43.0M-$262.0M
Repurchases of common stock$1.7B$2.5B$2.5B$2.5B$2.6B$1.6B

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$1.3B$660.0M$3.0B$3.1B$870.0M$895.0M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$5.0M$3.0M$9.0M——-$2.0M
Net increase (decrease) in cash—-$873.0M-$121.0M——-$100.0M

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interest paid$533.0M$539.0M$535.0M$622.0M$511.0M$569.0M
Income Taxes Paid, Net$358.0M$10.0M$136.0M$81.0M$1.5B-$5.0M